118 related articles for article (PubMed ID: 26360548)
41. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.
Jackson G; Taylor P; Smith GM; Marcus R; Smith A; Chu P; Littlewood TJ; Duncombe A; Hutchinson M; Mehta AB; Johnson SA; Carey P; MacKie MJ; Ganly PS; Turner GE; Deane M; Schey S; Brookes J; Tollerfield SM; Wilson MP
Br J Haematol; 2001 Jan; 112(1):127-37. PubMed ID: 11167793
[TBL] [Abstract][Full Text] [Related]
42. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
Wang L; Luo J; Chen G; Fang M; Wei X; Li Y; Liu Z; Zhang Y; Gao S; Shen J; Wang X; Gao X; Zhou W; Ma Y; Liu H; Li X; Yang L; Sun K; Yu L
Clin Epigenetics; 2020 Sep; 12(1):132. PubMed ID: 32873343
[TBL] [Abstract][Full Text] [Related]
43. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
[TBL] [Abstract][Full Text] [Related]
44. FLAG vs FLAG-IDA: outcomes in relapsed/refractory acute leukemias.
Farooq MU; Mushtaq F; Farooq A; Khan DH; Mir MA
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1191-1193. PubMed ID: 30887181
[TBL] [Abstract][Full Text] [Related]
45. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
[TBL] [Abstract][Full Text] [Related]
46. [Clinical Efficacy of Decitabine Combined with Modified CAG Regimen for Relapse/Refractory Acute Myeloid Leukemia with AML1-ETO
Liu Q; Fei XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1334-1338. PubMed ID: 27784352
[TBL] [Abstract][Full Text] [Related]
47. Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China.
Zhang X; Li Y; Zhang Y; Chen X; Zhang C; Gao L; Kong P; Liu Y; Wen Q; Zeng Y; Wang Q; Su Y; Wang C; Wang S; Yuan Z; Gao L
Leuk Res; 2013 Jun; 37(6):657-64. PubMed ID: 23537708
[TBL] [Abstract][Full Text] [Related]
48. FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects.
Visani G; Tosi P; Zinzani PL; Manfroi S; Ottaviani E; Cenacchi A; Carrara P; Clavio M; Gobbi M; Tura S
Eur J Haematol; 1996 May; 56(5):308-12. PubMed ID: 8641405
[TBL] [Abstract][Full Text] [Related]
49. [CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].
Takahashi W; Nakamura Y; Tadokoro J; Handa T; Arai H; Tokita K; Iso H; Tsurumi S; Sasaki K; Maki K; Mitani K
Rinsho Ketsueki; 2012 Jan; 53(1):71-7. PubMed ID: 22374527
[TBL] [Abstract][Full Text] [Related]
50. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia.
Qian SX; Li JY; Tian T; Shen YF; Jiang YQ; Lu H; Wu HX; Zhang SJ; Xu W
Leuk Res; 2007 Oct; 31(10):1383-8. PubMed ID: 17420048
[TBL] [Abstract][Full Text] [Related]
51. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
Quarello P; Berger M; Rivetti E; Galletto C; Masetti R; Manicone R; Barisone E; Pession A; Fagioli F
J Pediatr Hematol Oncol; 2012 Apr; 34(3):208-16. PubMed ID: 22395219
[TBL] [Abstract][Full Text] [Related]
52. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
53. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
Specchia G; Pastore D; Carluccio P; Liso A; Mestice A; Rizzi R; Ciuffreda L; Pietrantuono G; Liso V
Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203
[TBL] [Abstract][Full Text] [Related]
54. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
55. FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center.
Yılmaz Bengoa Ş; Ataseven E; Kızmazoğlu D; Demir Yenigürbüz F; Erdem M; Ören H
Turk J Haematol; 2017 Mar; 34(1):46-51. PubMed ID: 27095144
[TBL] [Abstract][Full Text] [Related]
56. Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia.
Reid JH; Marini BL; Benitez LL; Pettit K; Bixby DL; Burke P; Perissinotti AJ
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):393-400.e1. PubMed ID: 33612433
[TBL] [Abstract][Full Text] [Related]
57. Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine).
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Leuk Res; 2020 Jun; 93():106318. PubMed ID: 32127177
[TBL] [Abstract][Full Text] [Related]
58. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
[No Abstract] [Full Text] [Related]
59. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study.
Yamada K; Furusawa S; Saito K; Waga K; Koike T; Arimura H; Aoyagi A; Yamato H; Sakuma H; Tsunogake S
Leukemia; 1995 Jan; 9(1):10-4. PubMed ID: 7531259
[TBL] [Abstract][Full Text] [Related]
60. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
Tenold ME; Moskoff BN; Krishnan R; Rosenberg AS; Hoeg RT; Abedi M; Tuscano JM; Jonas BA
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e611-e618. PubMed ID: 33811007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]